Effects of SGLT2 Inhibitors and DPP-4 Inhibitors on Advanced Glycation End Products
Drug Res (Stuttg) DOI: 10.1055/a-2234-1797Clinical trials have revealed that sodium glucose cotransporter 2 (SGLT2)
inhibitors suppress the onset of heart failure and cardiovascular death in
diabetic patients. On the other hand, few reports have been published concerning
such effects of dipeptidyl peptidase-4 (DPP-4) inhibitors. We undertook the
present study to evaluate the effects of SGLT2 inhibitors and DPP-4 inhibitors
on the advanced glycation end products (AGEs), well known as a risk factor for
the development of cardiovascular disorders.Type 2 diabetes mellitus were divided into two groups and treated with either
SGLT2 inhibitors or DPP-4 inhibitors for 3 months. Before and after the 3-month
treatment period with each drug, the AGEs and diabetes-related parameters were
measured. Methylglyoxal-derived hydroimidazolone-1 (MG-H1) was measured as one
of the AGEs.In the SGLT2 inhibitor group, both the blood HbA1c and MG-H1 levels decreased
significantly after the 3-month treatment period. In the DPP-4 inhibitor group,
only the blood HbA1c level decreased significantly, with no significant change
of the blood MG-H1 level.SGLT2 inhibitor reduced both the blood levels of HbA1c and AGEs (MG-H1).
Considering that the blood levels of AGEs are associated with the risk of heart
failure and cardiovascular disorders, the results of the ...
Source: Drug Research - Category: Drugs & Pharmacology Authors: Kusunoki, Masataka Hisano, Fumiya Matsuda, Shin-ichi Kusunoki, Akiko Abe, Tomokazu Tsutsumi, Kazuhiko Miyata, Tetsuro Tags: Original Article Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Heart | Heart Failure | SGLT2 Inhibitors | Sodium | Study